To continue getting breaking news and the full stories from The Boston Globe, subscribe today.

The Boston Globe

Business

Boston.com

ImmunoGen rises after drug delays cancer worsening in study

By Bloomberg News

 |   

  March 30, 2012

ImmunoGen Inc. rose the most in almost a year after partner Roche Holding AG said a breast cancer drug delayed the disease worsening in a patient study. Patients who received the medicine, T-DM1, lived “significantly” longer without their disease progressing compared with those who received a combination of GlaxoSmithKline Plc’s Tykerb and Roche’s Xeloda, Basel, Switzerland-based Roche said in a statement today. Roche is developing T-DM1 with technology it licensed from ImmunoGen.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help